vs
FS Bancorp, Inc.（FSBW）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
FS Bancorp, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$40.0M vs $35.5M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 12.0%），FS Bancorp, Inc.自由现金流更多（$51.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 6.2%）
FS Bancorp, Inc.是总部位于美国的银行控股公司，为华盛顿第一安全银行的母公司，主要面向美国太平洋西北地区客户提供各类个人及商业银行服务，包括存款产品、住房贷款、小微企业融资、建筑贷款等，核心业务涵盖零售银行、商业银行及住房信贷三大板块。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FSBW vs RXRX — 直观对比
营收规模更大
FSBW
是对方的1.1倍
$35.5M
营收增速更快
RXRX
高出669.7%
12.0%
自由现金流更多
FSBW
多$99.3M
$-47.3M
两年增速更快
RXRX
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.0M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 25.8% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | 12.0% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $1.11 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBWRXRX
| Q4 25 | $40.0M | $35.5M | ||
| Q3 25 | $39.3M | $5.2M | ||
| Q2 25 | $37.3M | $19.2M | ||
| Q1 25 | $36.1M | $14.7M | ||
| Q4 24 | $35.7M | $4.5M | ||
| Q3 24 | $37.2M | $26.1M | ||
| Q2 24 | $36.3M | $14.4M | ||
| Q1 24 | $35.5M | $13.8M |
净利润FSBWRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $9.2M | $-162.3M | ||
| Q2 25 | $7.7M | $-171.9M | ||
| Q1 25 | $8.0M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $10.3M | $-95.8M | ||
| Q2 24 | $9.0M | $-97.5M | ||
| Q1 24 | $8.4M | $-91.4M |
毛利率FSBWRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率FSBWRXRX
| Q4 25 | 25.8% | -304.8% | ||
| Q3 25 | 29.5% | -3327.6% | ||
| Q2 25 | 26.2% | -916.8% | ||
| Q1 25 | 26.2% | -1297.9% | ||
| Q4 24 | 27.6% | -4042.4% | ||
| Q3 24 | 26.5% | -377.1% | ||
| Q2 24 | 31.3% | -697.4% | ||
| Q1 24 | 29.7% | -698.4% |
净利率FSBWRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 23.4% | -3135.3% | ||
| Q2 25 | 20.7% | -894.2% | ||
| Q1 25 | 22.2% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 27.6% | -367.5% | ||
| Q2 24 | 24.7% | -676.6% | ||
| Q1 24 | 23.7% | -662.4% |
每股收益（稀释后）FSBWRXRX
| Q4 25 | $1.11 | $-0.17 | ||
| Q3 25 | $1.18 | $-0.36 | ||
| Q2 25 | $0.99 | $-0.41 | ||
| Q1 25 | $1.01 | $-0.50 | ||
| Q4 24 | $0.88 | $-0.56 | ||
| Q3 24 | $1.29 | $-0.34 | ||
| Q2 24 | $1.13 | $-0.40 | ||
| Q1 24 | $1.06 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.2M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $307.7M | $1.1B |
| 总资产 | $3.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FSBWRXRX
| Q4 25 | $28.2M | $743.3M | ||
| Q3 25 | $61.3M | $659.8M | ||
| Q2 25 | $33.2M | $525.1M | ||
| Q1 25 | $62.7M | $500.5M | ||
| Q4 24 | $31.6M | $594.4M | ||
| Q3 24 | $40.3M | $427.6M | ||
| Q2 24 | $33.0M | $474.3M | ||
| Q1 24 | $45.4M | $296.3M |
总债务FSBWRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益FSBWRXRX
| Q4 25 | $307.7M | $1.1B | ||
| Q3 25 | $300.5M | $1.0B | ||
| Q2 25 | $297.2M | $919.1M | ||
| Q1 25 | $298.8M | $933.9M | ||
| Q4 24 | $295.8M | $1.0B | ||
| Q3 24 | $288.9M | $524.6M | ||
| Q2 24 | $284.0M | $584.4M | ||
| Q1 24 | $277.9M | $401.2M |
总资产FSBWRXRX
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.2B | $1.4B | ||
| Q2 25 | $3.2B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.0B | $726.5M | ||
| Q2 24 | $2.9B | $775.9M | ||
| Q1 24 | $3.0B | $557.8M |
负债/权益比FSBWRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $51.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 129.8% | -133.1% |
| 资本支出强度资本支出/营收 | 50.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $107.2M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FSBWRXRX
| Q4 25 | $72.3M | $-46.1M | ||
| Q3 25 | $44.6M | $-117.4M | ||
| Q2 25 | $7.1M | $-76.4M | ||
| Q1 25 | $8.2M | $-132.0M | ||
| Q4 24 | $50.8M | $-115.4M | ||
| Q3 24 | $-891.0K | $-59.2M | ||
| Q2 24 | $9.9M | $-82.2M | ||
| Q1 24 | $275.0K | $-102.3M |
自由现金流FSBWRXRX
| Q4 25 | $51.9M | $-47.3M | ||
| Q3 25 | $41.6M | $-117.6M | ||
| Q2 25 | $5.9M | $-79.6M | ||
| Q1 25 | $7.8M | $-133.8M | ||
| Q4 24 | $49.2M | $-116.7M | ||
| Q3 24 | $-1.5M | $-63.8M | ||
| Q2 24 | $9.6M | $-83.4M | ||
| Q1 24 | $-82.0K | $-109.0M |
自由现金流率FSBWRXRX
| Q4 25 | 129.8% | -133.1% | ||
| Q3 25 | 105.9% | -2272.5% | ||
| Q2 25 | 15.7% | -413.9% | ||
| Q1 25 | 21.7% | -907.4% | ||
| Q4 24 | 137.7% | -2567.7% | ||
| Q3 24 | -4.1% | -244.6% | ||
| Q2 24 | 26.6% | -578.5% | ||
| Q1 24 | -0.2% | -789.9% |
资本支出强度FSBWRXRX
| Q4 25 | 50.9% | 3.5% | ||
| Q3 25 | 7.7% | 4.7% | ||
| Q2 25 | 3.5% | 16.4% | ||
| Q1 25 | 1.0% | 12.4% | ||
| Q4 24 | 4.6% | 28.6% | ||
| Q3 24 | 1.7% | 17.5% | ||
| Q2 24 | 0.8% | 8.2% | ||
| Q1 24 | 1.0% | 48.2% |
现金转化率FSBWRXRX
| Q4 25 | — | — | ||
| Q3 25 | 4.86× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
